about 1 month ago
CNBC Oct 5, 2026

Russia hospitalizes almost 200 people after researcher’s death from plague: Reports

Nearly 200 individuals in Russia's Irkutsk region have been hospitalized and placed under medical observation following the death of a researcher from an unspecified form of the plague. The employee, who worked at an anti-plague research institute in Irkutsk, reportedly fell ill after returning from a work trip to the nearby Republic of Buryatia, where a plague outbreak had been noted near the Mongolian border. Local authorities took swift action due to the potential public health threat.

The regional health situation remains under close monitoring, with Russia's public health watchdog, Rospotrebnadzor, reporting that the overall sanitary and epidemiological conditions in Irkutsk, including the cities of Irkutsk and Shelekhov, are currently stable. Despite the severity of the case, expanded laboratory testing has yet to detect microorganisms directly related to the employee’s line of work, leaving questions about the exact contagion source.

This health scare has attracted international attention, with the White House publicly acknowledging that it is tracking developments related to this suspected plague exposure. According to reports, the U.S. administration is actively monitoring the outbreak and evaluating possible responses. However, official statements from Russian health authorities, the World Health Organization, and the U.S. State Department have not been immediately available to clarify the situation further.

Amid heightened concerns, former U.S. President Donald Trump is also expected to discuss the incident with Russian President Vladimir Putin in the near future. The ongoing situation highlights the rare but serious risk of plague outbreaks resurging in regions like Siberia, where endemic reservoirs of the disease still exist, emphasizing the need for vigilant public health surveillance and international cooperation.

0
0 Read source
Share this post
Facebook Twitter LinkedIn

Discussion

0 comments

No comments yet

Start the discussion with a take, question, or market read.